As of 2026-01-05, the EV/EBITDA ratio of Fate Therapeutics Inc (FATE) is -0.52. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FATE's latest enterprise value is 73.16 mil USD. FATE's TTM EBITDA according to its financial statements is -140.20 mil USD. Dividing these 2 quantities gives us the above FATE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.0x - 15.4x | 15.2x |
| Forward P/E multiples | 17.1x - 36.7x | 21.9x |
| Fair Price | (20.43) - (18.41) | (22.19) |
| Upside | -2171.3% - -1966.8% | -2350.0% |
| Date | EV/EBITDA |
| 2026-01-02 | -0.52 |
| 2025-12-31 | -0.52 |
| 2025-12-30 | -0.52 |
| 2025-12-29 | -0.53 |
| 2025-12-26 | -0.53 |
| 2025-12-24 | -0.54 |
| 2025-12-23 | -0.51 |
| 2025-12-22 | -0.57 |
| 2025-12-19 | -0.57 |
| 2025-12-18 | -0.57 |
| 2025-12-17 | -0.57 |
| 2025-12-16 | -0.61 |
| 2025-12-15 | -0.63 |
| 2025-12-12 | -0.66 |
| 2025-12-11 | -0.62 |
| 2025-12-10 | -0.61 |
| 2025-12-09 | -0.57 |
| 2025-12-08 | -0.59 |
| 2025-12-05 | -0.60 |
| 2025-12-04 | -0.62 |
| 2025-12-03 | -0.60 |
| 2025-12-02 | -0.54 |
| 2025-12-01 | -0.56 |
| 2025-11-28 | -0.65 |
| 2025-11-26 | -0.62 |
| 2025-11-25 | -0.58 |
| 2025-11-24 | -0.60 |
| 2025-11-21 | -0.56 |
| 2025-11-20 | -0.53 |
| 2025-11-19 | -0.57 |
| 2025-11-18 | -0.55 |
| 2025-11-17 | -0.51 |
| 2025-11-14 | -0.50 |
| 2025-11-13 | -0.53 |
| 2025-11-12 | -0.57 |
| 2025-11-11 | -0.63 |
| 2025-11-10 | -0.61 |
| 2025-11-07 | -0.59 |
| 2025-11-06 | -0.57 |
| 2025-11-05 | -0.61 |
| 2025-11-04 | -0.69 |
| 2025-11-03 | -0.75 |
| 2025-10-31 | -0.82 |
| 2025-10-30 | -0.77 |
| 2025-10-29 | -0.81 |
| 2025-10-28 | -0.94 |
| 2025-10-27 | -0.99 |
| 2025-10-24 | -1.07 |
| 2025-10-23 | -0.96 |
| 2025-10-22 | -0.94 |